secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-09-23T20:15:16+00:00
Accession:  0001193125-26-399425
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz extends $1.9B term loan to 2033, cuts margin by 50 bps
-----------------------------------------------------------

- Jazz Lux amended credit agreement to extend $1,895,000,000 term loans maturity from May 5, 2028 to May 5, 2033.
- Interest margin reduced by 50 bps: now Term SOFR + 1.75% or prime + 0.75%, with 0.50% SOFR floor.
- Borrowed $273,310,355.18 new Tranche B-3 loans to repay non-converted Tranche B-2 loans; total principal unchanged at $1,895,000,000.
- Loans amortize quarterly at 0.25% of initial principal, balance due at new 2033 maturity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/0001193125-26-399425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-399425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer